Clearwater Analytics (CWAN) Q4 2025 earnings review
Going Private on a High Note: Revenue Soars 72%
Clearwater Analytics delivered a transformative Q4, reporting $217.5M in revenue (+72% YoY) and $841M in ARR (+77% YoY), driven by the integration of recent acquisitions (Enfusion, Beacon). Despite the complexity of merging these entities, operational efficiency improved, with Non-GAAP Gross Margin hitting a record 79.2%. However, the primary narrative is the definitive agreement to be acquired by a Permira and Warburg Pincus-led group for $8.4B ($24.55/share). Consequently, management suspended guidance and cancelled the earnings call.
🐂 Bull Case
The $8.4 billion all-cash acquisition offer ($24.55/share) provides immediate, certain value to shareholders, eliminating execution risk regarding the long-term integration of Enfusion and Beacon.
Integrating lower-margin businesses usually compresses profitability. Clearwater defied this, expanding Non-GAAP Gross Margin to 79.2% (+40bps YoY) and Adjusted EBITDA Margin to 34.1% (+110bps YoY), validating their 'GenAI efficiency' thesis.
🐻 Bear Case
The company swung to a GAAP Net Loss of $12.5M (vs. massive income in 24Q4 driven by tax benefits), weighed down by transaction costs and increased interest expense ($15.2M vs $1.1M YoY) related to debt taken on for acquisitions.
While a definitive agreement is in place, the deal is subject to regulatory approvals and shareholder votes. Any antitrust hurdles or financing failures could leave the stock vulnerable, as it is currently trading on deal arbitrage.
⚖️ Verdict: ⚪
Neutral. Operationally, the company is performing exceptionally well (Accelerating growth, expanding margins). However, the investment thesis is now solely an arbitrage play on the $24.55 closing price expected in Q2 2026.
Key Themes
Take-Private Transaction
Clearwater entered a definitive agreement to be acquired by an investor group led by Permira and Warburg Pincus for ~$8.4 billion ($24.55/share in cash). The deal is expected to close in Q2 2026. This effectively caps upside but puts a floor under the valuation.
GenAI Driving Unit Economics
Management explicitly linked GenAI investments to record Non-GAAP gross margins (79.2%). They cite 'agentic workflows' reducing manual reconciliation by 90% and accelerating regulatory reporting by 80%. This technology layer is allowing them to scale revenue (+72%) faster than costs.
Debt Load & Interest Expense
Following the acquisition spree (Enfusion, Beacon), total debt net of issuance costs ballooned to $822.6M (vs $43.2M a year ago). Consequently, quarterly interest expense surged to $15.2M in Q4 2025 from just $1.1M in Q4 2024. While cash flow remains positive, the balance sheet is significantly more leveraged.
Stabilizing Net Retention
Net Revenue Retention (NRR) ticked up to 109%, from 108% in Q3 2025. While still below the 116% high-water mark of Q4 2024 (pre-acquisition dilution), the sequential improvement suggests cross-selling efforts between the core platform and acquired entities (Enfusion/Beacon) are gaining traction.
European Expansion Wins
The company secured major European wins, including Generali Deutschland (€40B AUM) and BarmeniaGothaer (€50B AUM). These wins validate the 'single instance' architecture's ability to handle complex European regulatory requirements and signal successful geographic diversification.
Other KPIs
Accelerating. Up 78% YoY. EBITDA margin expanded to 34.1% from 33.0% in the prior year period. This demonstrates strong operating leverage even while integrating substantial acquisitions.
Reversing. Swung to positive $52.3M from negative ($29.8M) in Q4 2024 (which was impacted by a one-time tax receivable agreement settlement). Operating cash flow remains healthy at $55.3M.
Decreased significantly from $177.4M in 24Q4 and down sequentially from Q2 levels, largely due to capital allocation toward acquisitions and share repurchases ($9.2M repurchased in Q4).
Guidance
Reversing. Due to the pending acquisition by the Investor Group, the company has suspended all forward-looking guidance and cancelled the earnings call. Previously, the company had been providing quarterly and annual outlooks.
Key Questions
Organic vs. Inorganic Split
With revenue up 72% driven by acquisitions, what is the standalone organic growth rate of the core Clearwater business? In Q3, organic ARR growth was noted as a concern (~17%); has this accelerated or decelerated?
Beacon & Enfusion Cross-Sell Velocity
NRR ticked up to 109%. How much of this improvement is driven by cross-selling Beacon risk modules into the Clearwater base versus organic upsell within the acquired customer bases?
Debt Paydown Capability
With $822M in debt and $91M in cash, and the company going private, what is the leverage ratio tolerance? Will free cash flow be sufficient to service this debt in a higher-rate environment if the deal were to unexpectedly fail?